Full-Time

US Medical Head

Rare Blood Disorders

Posted on 8/20/2026

Deadline 9/25/26
Sanofi

Sanofi

10,001+ employees

Global pharma company; vaccines and R&D

Compensation Overview

$266.3k - $443.8k/yr

Cambridge, MA, USA

Hybrid

Three days on-site per week required.

PharmD, PhD, MD

Category
Medical, Clinical & Veterinary (1)
Required Skills
Computer Networking
HIPAA

Get referred to Sanofi

See people who can refer or advise you

Requirements
  • An advanced degree in a scientific discipline, such as a Doctor of Medicine, Doctor of Philosophy, or Doctor of Pharmacy.
  • At least 15 years of experience in Medical Affairs, including at least 7 years leading a medical function.
  • At least 10 years of experience leading high-performing teams with a proven record of developing talent.
  • High ethical standards and the ability to comply with relevant ethical, regulatory, and legal standards.
  • A strong record of developing and executing medical strategies in key markets.
  • A proven record of building and maintaining a key opinion leader network in a key market.
  • Experience working across and building effective partnerships between departments in a global context.
  • Extensive experience and an excellent record dealing with safety issues.
  • Experience working within a complex international company and in a matrix environment.
Responsibilities
  • Provide leadership and focus to the US Medical Affairs Rare Blood Disorders team, foster teamwork and engagement, and attract, develop, and retain talent.
  • Lead the US Medical Rare Blood Disorders stakeholder engagement strategy.
  • Represent US Rare Blood Disorders Medical Affairs and Sanofi Specialty Care to external audiences, including healthcare professionals, key thought leaders, medical associations, and other organizations.
  • Develop and maintain key opinion leader relationships for the franchise and broader healthcare community.
  • Oversee insight gathering from healthcare stakeholders, including key opinion leaders, payers, and competent authorities.
  • Lead local data generation to support local market access and product life-cycle management.
  • Collaborate with health economics and Medical Managed Care teams to address questions and opportunities.
  • Ensure an appropriate data dissemination strategy for the US Immunology product portfolio within comprehensive stakeholder value propositions.
  • Oversee training and education events for internal and external stakeholders.
  • Ensure team compliance with external and internal guidelines and standard operating procedures, including Food and Drug Administration, Office of Inspector General, and Health Insurance Portability and Accountability Act requirements.
  • Ensure appropriate review and approval of medical and scientific content from Regulatory, Safety, Scientific Affairs, Medical Affairs, and Commercial functions.
  • Lead, plan, and provide medical expertise for US Rare Blood Disorders Medical programs.
  • Assess risks and identify issues, conflicts, or gaps across the brand and portfolio and provide guidance and solutions.
  • Implement measurable policies for customer and product medical education to support customer satisfaction and compliance.
  • Oversee management of the franchise medical budget and align key partners and programs with US Rare Blood Disorders Medical Affairs priorities.
  • Collaborate with other therapeutic areas to leverage US Rare Blood Disorders Medical Affairs expertise and programs.
Desired Qualifications
  • Advanced training certification in Hematology.
  • Experience in Medical Affairs Rare Hematology.
  • An entrepreneurial vision with strong execution.
  • Interpersonal communication, negotiation, and networking skills.
  • Critical thinking and problem-solving skills.
  • Planning, project management, time management, budget management, and resource or portfolio allocation skills.

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 sales rose 17.8%; Dupixent topped €5.2 billion for the quarter.
  • July 30 upgraded 2026 guidance to around 10% sales growth, with higher EPS.
  • August 4 MenQuadfi infant approval widens vaccine reach; Nexviazyme's June phase 3 readout strengthens pipeline.

What critics are saying

  • Dupixent faces tougher H2 2026 comparisons, threatening growth after the €5.2 billion quarter.
  • Cenrifki carries liver injury risk; strict monitoring can slow adoption and invite liability.
  • Dupixent concentration and Regeneron's November 2024 lawsuit threaten Sanofi's core growth engine.

What makes Sanofi unique

  • Dupixent and partnered launch engine generate repeatable immunology cash flows across geographies.
  • Sanofi converted 2026 approvals for Sarclisa Escena, Wayrilz, and Cenrifki into launches.
  • Paulo Fontoura's September 1 R&D mandate centralizes translational science and regulatory execution.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

Business Wire
Aug 13th, 2026
Epicrispr Biotechnologies Closes $90 Million Oversubscribed Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD

Epicrispr Biotechnologies Closes $90 Million Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD

Morningstar
Aug 12th, 2026
InduPro raises $77M Series B, doses first patient in Phase 1 trial of bispecific ADC for lung cancer

InduPro has closed a $77 million Series B financing round and dosed its first patient in a Phase 1 study of IDP-001, its lead oncology programme. The biotechnology company is developing IDP-001, a bispecific antibody-drug conjugate targeting EGFR and a novel tumour-associated proximity antigen, for treating advanced squamous non-small cell lung cancer and other solid tumours. The Column Group led the financing round, with participation from Vida Ventures, MRL Ventures Fund, Emerson Collective, Euclidean Capital, Solasta Ventures, Sanofi, and Eli Lilly and Company. Proceeds will support Phase 1 clinical development and early proof-of-concept data generation for IDP-001, whilst advancing InduPro's broader preclinical pipeline. InduPro uses a proximity-guided platform to map protein spatial relationships on cell surfaces for discovering selective co-target pairs.

FinancialContent
Jul 24th, 2026
Scribe Therapeutics prices upsized $129M IPO at top of range

Scribe Therapeutics, a clinical-stage biotechnology company developing in vivo CRISPR technologies, has priced its upsized initial public offering at $15.00 per share, the high end of its range. The company is offering 8,580,000 shares, expecting to raise $128.7 million in gross proceeds before fees and expenses. Scribe has also granted underwriters a 30-day option to purchase up to 1,287,000 additional shares. The shares are expected to begin trading on the Nasdaq Global Market on 24 July 2026 under the ticker symbol "SCTX", with the offering closing on 27 July 2026. Additionally, Scribe has agreed to sell 500,000 shares at the same price to Sanofi in a concurrent private placement. Leerink Partners, Goldman Sachs, Guggenheim Securities, and Wells Fargo Securities are serving as joint book-running managers.

Associated Press
Jul 10th, 2026
Sanofi's Sarclisa Escena approved in US as first anticancer drug delivered via on-body injector

The US Food and Drug Administration has approved Sanofi's subcutaneous Sarclisa Escena for treating multiple myeloma, making it the first anticancer treatment administered through an on-body injector. The therapy uses Enable Injections' CirCLIQ device, which delivers the drug automatically with a retractable 30g needle. The approval was supported by the IRAKLIA phase 3 study, which demonstrated that Sarclisa Escena delivered via the on-body injector provided similar efficacy and safety compared to intravenous infusion, with significantly shorter treatment time and fewer infusion-related reactions. The study showed a 71.1% objective response rate in patients with relapsed or refractory multiple myeloma. More than 70,000 patients worldwide have been treated with Sarclisa-based regimens. The on-body injector aims to reduce physical burden on healthcare providers whilst offering patients greater convenience during treatment.

Yahoo Finance
Jul 5th, 2026
Sanofi appoints Paulo Fontoura as R&D chief to accelerate pharma pipeline transformation

Sanofi has appointed Paulo Fontoura as Executive Vice President and Global Head of Research & Development Pharma, effective 1 September. Based in Paris, Fontoura will oversee the company's innovation engine, spanning research, translational medicine, clinical development, and regulatory affairs. He succeeds Dr Houman Ashrafian, who is leaving to pursue new opportunities. Fontoura brings over 25 years of experience across academic medicine, translational science, and pharmaceutical innovation. The appointment comes as Sanofi drives an R&D transformation whilst progressing its pipeline across multiple therapeutic areas. Separately, MacroGenics confirmed it will receive $24.5 million in regulatory milestone payments from Sanofi following FDA accelerated approval of TZIELD to delay decline in endogenous insulin production in children. Sanofi is a global biopharmaceutical company focusing on immunology, rare diseases, and oncology.